Constitutional alterations of the ATM gene in early onset sporadic breast cancer
After initial denaturation at 94°C for five minutes, each of the 35 cycles of amplification consisted of 30 seconds at 94°C, 30 seconds at optimal annealing temperature, 30 seconds at 72°C, followed by final extension of five minutes at 72°C. The oligonucleotide primer pairs used to amplify all...
Saved in:
Published in | Journal of medical genetics Vol. 39; no. 10; pp. 751 - 753 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group Ltd
01.10.2002
BMJ BMJ Publishing Group LTD BMJ Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | After initial denaturation at 94°C for five minutes, each of the 35 cycles of amplification consisted of 30 seconds at 94°C, 30 seconds at optimal annealing temperature, 30 seconds at 72°C, followed by final extension of five minutes at 72°C. The oligonucleotide primer pairs used to amplify all the ATM coding exons have been described previously, with conditions for each pair. 19 Single strand conformation polymorphism (SSCP)/heteroduplex (HTX) analysis was performed as previously described. 20 Briefly, 10 [micro]l of PCR products containing 10 [micro]l non-denaturing loading buffer were boiled for five minutes, chilled on ice for 10 minutes, and loaded on a 6% MDE acrylamide gel (FMC Bioproducts, Rockland, ME, USA). The 11q23 locus encompassing the ATM gene is often deleted in breast carcinoma and reduction in the levels of ATM mRNA and protein has also been observed in this type of tumour. 24 In addition, somatic alterations of ATM have been reported in lymphoproliferative disorders. 22, 25, 26 Interestingly, by revealing missense mutations and complex intragenic rearrangements, the spectrum of somatic mutations found in these malignancies differs from that of classical AT patients, leading to the suggestion that there may exist two classes of ATM mutations, that is, the "null" mutations (complete/near complete loss of function) and the "impairing" mutations (reduced function). |
---|---|
Bibliography: | href:jmedgenet-39-751.pdf Correspondence to: Dr P Maillet, Unit of Identification of Genetic Predispositions to Cancer, CMU/Laboratory of Oncology 5216, 1 rue Michel Servet, CH-1211 Geneva 4, Switzerland; Philippe.Maillet@medecine.unige.ch istex:C5DDCAF687A8715FE19EA684BAA2F1B19C039849 local:0390751 PMID:12362033 ark:/67375/NVC-1NCHZ67K-N SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Correspondence-1 |
ISSN: | 0022-2593 1468-6244 1468-6244 |
DOI: | 10.1136/jmg.39.10.751 |